Large companies rarely make cold acquisition offers. The typical path is a gradual process starting with a partnership or a small investment. This allows the acquirer to conduct due diligence from the inside, understand the startup's value, and build relationships before escalating to a full buyout.

In a tight funding environment, a significant portion of startups now secure pharma partnerships *before* their Series A. This pre-validation has become a major draw for VCs, signaling a shift where corporate buy-in is needed to de-risk early-stage science for investors.

Big Pharma operates less like a traditional manufacturer and more like a venture capital firm, managing a portfolio of high-risk assets (drug targets) and allocating capital accordingly. This mental model explains their focus on platform technologies that improve the success rate of their portfolio bets.

A successful exit is a highly choreographed dance, not an abrupt decision. Founders should spend years building relationships with line-of-business leaders—not just Corp Dev—at potential acquiring companies. The goal is to 'incept' the idea of an acquisition long before it's needed.

For years, Actuate's CEO has shared progress with large pharma companies, not just for early deal-making, but to get critical feedback on their development plan. This helps them understand what data potential acquirers need to see to make a compelling offer later.

Instead of waiting for a formal sale process, Tourmaline began discussions with strategic partners as soon as their Phase 2 trial started. This proactive approach is about creating future options, gauging interest, and building relationships long before an exit is imminent, a crucial strategy for capital-intensive drug development.

Founders who wait until they need to sell have already failed. A successful exit requires a multi-year 'background process' of building relationships. The key is to engage with SVPs and business unit leaders at potential acquirers—the people who will champion the deal internally—not just the Corp Dev team who merely execute transactions.

Vivtex's $2.1B deal with Novo Nordisk wasn't from a single pitch; it was cultivated over many years, stemming from pre-existing academic relationships. The key was building mutual scientific trust by consistently sharing progress—and even failures—allowing Novo Nordisk to observe their journey long-term.

The landmark partnership with Novo Nordisk wasn't won through a sales pitch. It was the result of a multi-year scientific relationship built on transparency. Consistently presenting progress, including failures, at conferences established deep institutional trust and credibility that proved invaluable.